NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announces it has completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. With the acquisition, NeoGenomics strengthens its commercial presence in the Northeast U.S. and broadens access to its comprehensive oncology test menu, expands its service capabilities, and accelerates growth in molecular and hematology-oncology testing.
Read the full article: NeoGenomics Completes Acquisition of Pathline //
Source: https://www.businesswire.com/news/home/20250407427587/en/NeoGenomics-Completes-Acquisition-of-Pathline